In my experience, lively biotechs can have several CT's per annum.
EXEL's been averaging 3 or 4 / year since 2010.
Of course, there's always the chance that it's a declined buy-out offer...
...or a declined partnership offering...or technical trial data lacking the appropriate forum for acceptable industry pronouncement.
Your guess is as good as anyone's...JMHO